508 related articles for article (PubMed ID: 34690210)
1. Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease.
Mori A; Mitsuyama K; Sakemi R; Yoshioka S; Fukunaga S; Kuwaki K; Yamauchi R; Araki T; Yoshimura T; Yamasaki H; Tsuruta K; Morita T; Yamasaki S; Tsuruta O; Torimura T
Kurume Med J; 2021 Dec; 66(4):209-215. PubMed ID: 34690210
[TBL] [Abstract][Full Text] [Related]
2. Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization.
Fukunaga S; Kuwaki K; Mitsuyama K; Takedatsu H; Yoshioka S; Yamasaki H; Yamauchi R; Mori A; Kakuma T; Tsuruta O; Torimura T
Int J Mol Med; 2018 Jan; 41(1):107-118. PubMed ID: 29115397
[TBL] [Abstract][Full Text] [Related]
3. Effect of Ramadan intermittent fasting on inflammatory markers, disease severity, depression, and quality of life in patients with inflammatory bowel diseases: A prospective cohort study.
Negm M; Bahaa A; Farrag A; Lithy RM; Badary HA; Essam M; Kamel S; Sakr M; Abd El Aaty W; Shamkh M; Basiony A; Dawoud I; Shehab H
BMC Gastroenterol; 2022 Apr; 22(1):203. PubMed ID: 35462542
[TBL] [Abstract][Full Text] [Related]
4. [Significance of serum calprotectin in assessing inflammatory bowel disease activity].
Mao JY; Li L; Pang Z
Zhonghua Yi Xue Za Zhi; 2017 Oct; 97(38):3001-3004. PubMed ID: 29061007
[No Abstract] [Full Text] [Related]
5. Pancreatitis-associated protein does not predict disease relapse in inflammatory bowel disease patients.
Nunes T; Etchevers MJ; Sandi MJ; Pinó Donnay S; Grandjean T; Pellisé M; Panés J; Ricart E; Iovanna JL; Dagorn JC; Chamaillard M; Sans M
PLoS One; 2014; 9(1):e84957. PubMed ID: 24416322
[TBL] [Abstract][Full Text] [Related]
6. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
7. Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease.
Shimoyama T; Yamamoto T; Yoshiyama S; Nishikawa R; Umegae S
Inflamm Bowel Dis; 2023 Sep; 29(9):1399-1408. PubMed ID: 36334015
[TBL] [Abstract][Full Text] [Related]
8. Serum leucine-rich alpha-2 glycoprotein and calprotectin in children with inflammatory bowel disease: A multicenter study in Japan.
Yasuda R; Arai K; Kudo T; Nambu R; Aomatsu T; Abe N; Kakiuchi T; Hashimoto K; Sogo T; Takahashi M; Etani Y; Kato K; Yamashita Y; Mitsuyama K; Mizuochi T
J Gastroenterol Hepatol; 2023 Jul; 38(7):1131-1139. PubMed ID: 36880154
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease.
Yoshimura T; Mitsuyama K; Sakemi R; Takedatsu H; Yoshioka S; Kuwaki K; Mori A; Fukunaga S; Araki T; Morita M; Tsuruta K; Yamasaki H; Torimura T
Mediators Inflamm; 2021; 2021():8825374. PubMed ID: 33623482
[TBL] [Abstract][Full Text] [Related]
10. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
[TBL] [Abstract][Full Text] [Related]
11. Serum galectins as potential biomarkers of inflammatory bowel diseases.
Yu TB; Dodd S; Yu LG; Subramanian S
PLoS One; 2020; 15(1):e0227306. PubMed ID: 31929564
[TBL] [Abstract][Full Text] [Related]
12. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
[TBL] [Abstract][Full Text] [Related]
13. Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases.
Kalla R; Kennedy NA; Ventham NT; Boyapati RK; Adams AT; Nimmo ER; Visconti MR; Drummond H; Ho GT; Pattenden RJ; Wilson DC; Satsangi J
Am J Gastroenterol; 2016 Dec; 111(12):1796-1805. PubMed ID: 27596694
[TBL] [Abstract][Full Text] [Related]
14. The use of serum calprotectin as a biomarker for inflammatory activity in inflammatory bowel disease.
Suárez Ferrer C; Abadía Barno M; Martín Arranz E; Jochems A; García Ramírez L; Poza Cordón J; Jaquotot Herranz M; Cerpa Arencibia A; Martín Arranz MD
Rev Esp Enferm Dig; 2019 Oct; 111(10):744-749. PubMed ID: 31476872
[TBL] [Abstract][Full Text] [Related]
15. Pancreatitis-associated protein has no additional value as a marker of disease activity in a real-life cohort of IBD patients.
Bodelier AG; Pierik MJ; van den Heuvel T; Bovee-Oudenhoven IM; de Boer E; Hameeteman W; Masclee AA; Jonkers D
Eur J Gastroenterol Hepatol; 2014 Aug; 26(8):902-9. PubMed ID: 24915490
[TBL] [Abstract][Full Text] [Related]
16. TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease.
Grimstad T; Skoie IM; Doerner J; Isaksen K; Karlsen L; Aabakken L; Omdal R; Putterman C
Scand J Gastroenterol; 2017 Apr; 52(4):420-424. PubMed ID: 28040992
[TBL] [Abstract][Full Text] [Related]
17. Altered fecal bile acid composition in active ulcerative colitis.
Sommersberger S; Gunawan S; Elger T; Fererberger T; Loibl J; Huss M; Kandulski A; Krautbauer S; Müller M; Liebisch G; Buechler C; Tews HC
Lipids Health Dis; 2023 Nov; 22(1):199. PubMed ID: 37980492
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
19. Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease.
Samant H; Desai D; Abraham P; Joshi A; Gupta T; Dherai A; Ashavaid T
Indian J Gastroenterol; 2015 Nov; 34(6):431-5. PubMed ID: 26589229
[TBL] [Abstract][Full Text] [Related]
20. Serum Calprotectin in Adolescents With Inflammatory Bowel Disease-A Pilot Investigation.
Carlsen K; Malham M; Hansen LF; Petersen JJH; Paerregaard A; Houen G; Wewer V
J Pediatr Gastroenterol Nutr; 2019 May; 68(5):669-675. PubMed ID: 30628981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
